Literature DB >> 2111434

Outbreak of multidrug-resistant tuberculosis--Texas, California, and Pennsylvania.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2111434

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN： 0149-2195            Impact factor:   17.586


× No keyword cloud information.
  10 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  MULTIDRUG RESISTANT TUBERCULOSIS - BIOMECHANISM, EPIDEMIOLOGY AND MANAGEMENT STRATEGIES.

Authors:  S C Tewari; S P Kalra; S Dangwal; R S Chatterji
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 3.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

4.  DNA fngerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future.

Authors:  Scott J N McNabb; Christopher R Braden; Thomas R Navin
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

5.  Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

Authors:  Patrick K Moonan; Teresa N Quitugua; Janice M Pogoda; Gary Woo; Gerry Drewyer; Behzad Sahbazian; Denise Dunbar; Kenneth C Jost; Charles Wallace; Stephen E Weis
Journal:  BMC Public Health       Date:  2011-01-07       Impact factor: 3.295

6.  Tuberculosis poor treatment outcomes and its determinants in Kilifi County, Kenya: a retrospective cohort study from 2012 to 2019.

Authors:  Geoffrey G Katana; Moses Ngari; Teresia Maina; Deche Sanga; Osman A Abdullahi
Journal:  Arch Public Health       Date:  2022-02-05

7.  Making state public health laws work for SARS outbreaks.

Authors:  Edward P Richards; Katherine C Rathbun
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

8.  The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia.

Authors:  Thaddeus L Miller; Andra Cirule; Fernando A Wilson; Timothy H Holtz; Vija Riekstina; Kevin P Cain; Patrick K Moonan; Vaira Leimane
Journal:  Cost Eff Resour Alloc       Date:  2013-04-17

9.  Medical information systems: a foundation for healthcare technologies in developing countries.

Authors:  Gari D Clifford; Joaquin A Blaya; Rachel Hall-Clifford; Hamish Sf Fraser
Journal:  Biomed Eng Online       Date:  2008-06-11       Impact factor: 2.819

10.  Double Standards in Global Health: Medicine, Human Rights Law and Multidrug-Resistant TB Treatment Policy.

Authors:  Thomas Nicholson; Catherine Admay; Aaron Shakow; Salmaan Keshavjee
Journal:  Health Hum Rights       Date:  2016-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.